Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Genmab acquires the Dutch biotech for $8bn.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
BNT329 enters the clinic, as do four other new ADCs.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
